

Vesna ŽIVKOVIĆ<sup>1</sup>  
Vuka KATIĆ<sup>1</sup>  
Aleksandar NAGORNI<sup>2</sup>  
Jasmina GLIGORIJEVIĆ<sup>1</sup>  
Danijela BENEDETO-STOJANOV<sup>2</sup>

Goran BJELAKOVIĆ<sup>2</sup>  
Aleksandar PETROVIĆ<sup>3</sup>  
Zlatibor ANĐELKOVIĆ<sup>4</sup>  
Violeta GROZDANOVIĆ<sup>3</sup>

<sup>1</sup>INSTITUTE OF PATHOLOGY, MEDICAL SCHOOL NIŠ, SERBIA AND MONTENEGRO;  
<sup>2</sup>CLINIC OF GASTROENTEROLOGY, MEDICAL SCHOOL NIŠ, SERBIA AND MONTENEGRO;  
<sup>3</sup>INSTITUTE OF HISTOLOGY, MEDICAL SCHOOL NIŠ, SERBIA AND MONTENEGRO;  
<sup>4</sup>INSTITUTE OF HISTOLOGY, MEDICAL SCHOOL KOŠOVSKA MITROVICA, SERBIA AND MONTENEGRO

# Histopathological and immunohistochemical features of dysplasia-associated lesions or masses in ulcerative colitis

**KEYWORDS:** Colitis, Ulcerative; Colonic Polyps; Cytodiagnosis; Immunohistochemistry; Ki-67 Antigen

## INTRODUCTION

Dysplasia that arises in association with chronic ulcerative colitis is the most important marker of an increased risk of malignancy in patients with this disease. Dysplasia in ulcerative colitis may be classified as flat and elevated (dysplasia associated lesion or mass [DALM]) (1). DALMs are frequently associated with a high proportion of colorectal carcinoma and are an indication for colectomy (1). DALMs are subdivided into "adenoma-like" and "non-adenoma-like" lesions based on their endoscopic appearance (2). "Adenoma-like" lesions (defined as a polyp in which distinction from a sporadic adenoma was not possible) may be treated by polypectomy alone (2). However, molecular data suggest that the "adenoma-like" DALM may have different molecular genotype than adenoma (3,4). Patients with a "non-adenoma-like" DALM (irregular, broad bases, or structured lesion), regardless of the grade dysplasia, should be treated with colectomy because of the high probability of adenocarcinoma (2). The purpose of this study was to identify morphological characteristics of DALMs in chronic ulcerative colitis, and location and intensity of Ki-67 immunostaining, and to evaluate the prognostic significance of Ki-67 expression.

## MATERIAL AND METHODS

Polypectomy specimens from 21 chronic ulcerative colitis patients with DALM were available. The formalin-fixed and paraffin-embedded tissue blocks were sectioned at 5 micrometer and were stained with hematoxylin and eosin for histological evaluation. Immunostaining with anti-Ki-67 antibody (Dako, Copenhagen) was used to evaluate proliferative activity. The immunohistochemical staining was visualized using LSAB (labeled streptavidin-biotin) method.

Address correspondence to:  
Prof. Dr. Vesna Živković, Institute of Pathology, Medical School of Niš, 18000 Niš, Serbia and Montenegro, E-mail: vekivz@eunet.yu

The manuscript was received: 15. 02. 2004.  
Provisionally accepted: 15.03.2004.  
Accepted for publication: 23.03.2004.

## RESULTS

Lesions are tubulo-villous or villous and frequently show admixture of dysplastic and regular crypts toward the surface. In low-grade dysplasia, the epithelium is composed of basally oriented, slightly pseudostratified cells with pencil-shaped hyperchromatic nuclei, increased mitotic figures and a lack of surface maturation. High-grade dysplasia is characterized by extension of the elongated nuclei to the upper part of cells, increasing hyperchromatism and the appearance of loss polarity. In low-grade dysplasia, Ki-67 immunoreactivity is prominent in the cells in the superficial mucosa as well as in cells at the crypt bases. In high-grade dysplasia, Ki-67 is diffusely distributed throughout the crypts, suggesting complete deregulation of normal cell proliferation. The intensity of the staining and the percentage of cells staining positively with Ki-67 tend to be greater in areas of high-grade dysplasia.

## CONCLUSION

We conclude that Ki-67 immunostaining can be an aid the diagnosis of dysplasia in ulcerative colitis. Additional studies such as flow cytometry and molecular techniques may help to secure the diagnosis DALM in the future. Colonoscopic surveillance of chronic ulcerative colitis may identify patients with DALMs and thereby prevent malignant transformation.

## REFERENCES

1. Blackstone MO, Riddell RH, Rogers BH, Levin B. Dysplasia-associated lesion or masses (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. *Gastroenterology* 1981;80:366-74.
2. Odze RB, Brown CA, Hartman CJ, Noffsinger AE, Fogt F. Genetic alteration in chronic ulcerative colitis-associated adenoma-like DALMs are similar to non-collitic sporadic adenomas. *Am J Surg Pathol* 2000;24:1209-16.
3. Walsh SV, Loda M, Torres CM, Antonioli D, Odze RD. P53 and beta catenin expression in chronic ulcerative colitis-associated polypoid dysplasia and sporadic adenomas: an immunohistochemical study. *Am J Surg Pathol* 1999;23:963-9.
4. Fogt F, Urbanski SJ, Sanders ME et al. Distinction between dysplasia-associated lesion or mass (DALM) and adenoma in patients with ulcerative colitis. *Hum Pathol* 2000;31:288-91.